Medplus Health Services Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company is focusing on strengthening backend operations, expanding their store network, and enhancing warehouses to support growth. - There are no direct references to raising capital via debt or equity markets in the Q3 2025 earnings call excerpts. - The management emphasizes operational efficiency, profitability, and sustainable growth rather than discussing fundraising activities. - If fundraising plans exist, they are not disclosed in this call or the pages provided.

- MedPlus is investing in strengthening its backend operations and infrastructure for long-term scalability and seamless execution. - Four new warehouses have been added recently to enhance availability at existing stores and support new store openings. - Additional warehouses planned: Hubli, Madurai, Agra (2), Vijayawada, Vizag, Kapai, Nagpur, Raipur, and Indore, totaling about 10 smaller warehouses (30,000 to 50,000 sq. ft. each). - These warehouses aim to improve supply chain efficiency, better serve current stores, and enable faster expansion into new areas and states. - The focus is on operational efficiency rather than large-scale capex; warehouse leases and related rent costs are already reflected in expenses. - Store additions planned around 600 stores annually, supported by the new warehouse network. Overall, capital investments are strategically focused on warehouse network expansion and backend operational infrastructure to support next growth phases.

- Private label sales expected to grow by about 1% per quarter on MRP basis, adding 15-20 basis points to gross margin quarterly. - Network expansion targeted at around 600 new stores annually starting FY '26, supporting sales growth. - Store same-store sales growth (SSSG) aimed to be around 4-5%, with focus on market share and profitability rather than just sales growth. - Total pharmacy GMV growth expected to be in line with typical pharma market growth plus inflation, around low double digits (15-16% sales growth combining store addition and SSSG). - Gross margins expected to improve modestly with private label penetration increasing from current ~68% to ~75-77% of products. - EBITDA margins around 5.1% considered sustainable, with slight upside possible but largely dependent on pace of store additions. - Efficiency improvements anticipated from new warehouses facilitating faster supply chain and better store support.

- MedPlus expects steady profitability levels with store-level EBITDA margins around 10-11%, sustainable over the next 2-3 years. - Same-store sales growth (SSSG) of 4-5% is targeted as a sustainable rate over the next 2-3 years, aiding fixed cost absorption. - Private label sales are expected to grow by approximately 1% volume (MRP) each quarter, contributing 15-20 basis points margin expansion quarterly. - Gross margins have scope to improve mainly through expanding private label penetration from current levels (~20% GMV pharma sales) to about 75-77%. - EBITDA margin crossed 5% (pharmacy business) and is viewed as a sustainable baseline with potential modest upside depending on store addition pace. - New warehouses and backend improvements are expected to support scaling but may add upfront costs initially. - Store additions planned around 600 annually, with disciplined focus on profitability over pure expansion.

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for MedPlus Health Services Limited. The discussion primarily focuses on: - Store expansion plans (net additions expected around 300 stores in the financial year) - Growth and profitability metrics like same-store sales growth (SSSG) and private label penetration - Operational aspects such as delivery services (2-hour delivery in select urban stores) and warehouse expansions to support growth - Margin impacts and supply chain considerations - No direct reference to order book or pending order backlog figures is provided in the transcript. Therefore, specific data on order book or pending orders is not available from the given document.